Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | 0.00% | -12.73% | -58.62% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.93M 3.23M 4.41M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
Latest transcript on Altamira Therapeutics
1 week | -12.73% | ||
Current month | -8.28% | ||
1 month | -21.31% | ||
3 months | -19.10% | ||
6 months | -28.00% | ||
Current year | -58.62% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Date | Price | Change |
---|---|---|
24-05-14 | 1.44 | 0.00% |
24-05-13 | 1.44 | -0.69% |
24-05-10 | 1.45 | -3.33% |
24-05-09 | 1.5 | +2.04% |
24-05-08 | 1.47 | -6.96% |
Delayed Quote Nasdaq, May 14, 2024 at 04:30 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock